July 25th 2024
Initial approval for maralixibat was granted on March 13, 2024, to treat PFIC patients aged 5 years and older.
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Pediatric patients with AD have an increased risk of type 2 inflammatory diseases
July 13th 2022A better understanding of this atopic diathesis and the atopic march often seen in pediatric patients is necessary to optimally treat and manage the patient population, ideally in a multidisciplinary setting.
Secukinumab receives expanded approvals in EU for pediatric arthritic conditions
July 5th 2022The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.
Provocative poster sessions abound at the SPD 2022 47th Annual Meeting
July 3rd 2022You will find dermatologic studies from the rare (annual erythema of infancy) to the common (atopic dermatitis) and lots in between at the poster sessions at this year's SPD 2022 47th Annual Meeting in Indianapolis, Indiana.